Title: Cromolyn
CAS Registry Number: 16110-51-3
CAS Name: 5,5¢-[(2-Hydroxy-1,3-propanediyl)bis(oxy)]bis[4-oxo-4H-1-benzopyran-2-carboxylic acid]
Additional Names: 5,5¢-[(2-hydroxytrimethylene)dioxy]bis(4-oxo-4H-1-benzopyran-2-carboxylic acid); 5,5¢-(2-hydroxytrimethylenedioxy)bis(4-oxochromene-2-carboxylic acid); 1,3-bis(2-carboxychromon-5-yloxy)-2-hydroxypropane; 1,3-di(2-carboxy-4-oxochromen-5-yloxy)propan-2-ol; cromoglycic acid
Molecular Formula: C23H16O11
Molecular Weight: 468.37
Percent Composition: C 58.98%, H 3.44%, O 37.58%
Literature References: Chromone complex which blocks mast cell degranulation. Prepn: NL 6603997; C. Fitzmaurice, T. B. Lee, US 3419578 (1966, 1968 both to Fisons). Metabolism: M. J. Ashton et al., Toxicol. Appl. Pharmacol. 26, 319 (1973). Mechanism of action: T. C. Theoharides et al., Science 207, 80 (1980); R. G. Alvarez et al., Agents Actions 11, 94 (1981). Toxicology in primates: J. E. Beach et al., Toxicol. Appl. Pharmacol. 57, 367 (1981). Clinical study in allergic conjunctivitis: G. A. Friday et al., Am. J. Ophthalmol. 95, 169 (1983). Review of pharmacology and clinical use: G. G. Shapiro, P. Konig, Pharmacotherapy 5, 156-170 (1985). Review: J. S. G. Cox in Pharmacological and Biochemical Properties of Drug Substances vol. 1, M. E. Goldberg, Ed. (Am. Pharm. Assoc., Washington, DC, 1977) pp 277-310; W. Storms, M. A. Kaliner, J. Asthma 42, 79-89 (2005).
Properties: mp 241-242° (dec).
Melting point: mp 241-242° (dec)
Derivative Type: Monohydrate
Properties: Colorless crystals from ethanol + ether, mp 216-217° (dec).
Melting point: mp 216-217° (dec)
Derivative Type: Disodium salt
CAS Registry Number: 15826-37-6
Additional Names: Cromolyn sodium; disodium cromoglycate; DSCG
Manufacturers' Codes: FPL-670
Trademarks: Alloptrex (Fabre); Allergocrom (Ursapharm); Colimune (Sanofi-Aventis); Cromabak (Th); Cromadoses (Th); Cromedil (Europhta); Cromogen (Ivax); Cromoptic (Chauvin); Duracroman (Merck KGaA); Gastrofrenal (Sigma-Tau); Hay-Crom (Ivax); Intal (Sanofi-Aventis); Intercron (Zambon); Lomudal (Sanofi-Aventis); Lomupren (Sanofi-Aventis); Lomusol (Sanofi-Aventis); Multicrom (Menarini); Nalcrom (Sanofi-Aventis); Nalcron (Sanofi-Aventis); Nasalcrom (Pharmacia & Upjohn); Ophtacalm (Chauvin); Opticrom (Sanofi-Aventis); Rynacrom (Sanofi-Aventis); Vividrin (Mann)
Molecular Formula: C23H14Na2O11
Molecular Weight: 512.33
Percent Composition: C 53.92%, H 2.75%, Na 8.97%, O 34.35%
Properties: Hygroscopic. Freely sol in water (100 mg/ml at 20°). Practically insol in chloroform and alcohol. LD50 in mice, rats (mg/kg): >8000 orally (Cox).
Toxicity data: LD50 in mice, rats (mg/kg): >8000 orally (Cox)
Therap-Cat: Antiasthmatic; antiallergic.
Therap-Cat-Vet: Antiallergic.
Keywords: Antiallergic; Antiasthmatic (Nonbronchodilator).
Cropropamide Croscarmellose Sodium Crotamiton Crotethamide Croton Oil

Cromoglicic acid
Cromoglicic acid.svg
Cromolyn ball-and-stick animation.gif
Systematic (IUPAC) name
5,5′-(2-hydroxypropane-1,3-diyl)bis(oxy)bis(4-oxo-4H-chromene-2-carboxylic acid)
Clinical data
AHFS/ International Drug Names
Pregnancy cat. B
Legal status inhaler POM, eye OTC(UK) nasal OTC, eye, inhaler Rx(US)
Routes topical: oral, nasal spray, inhaled, eye drops
Pharmacokinetic data
Bioavailability 1%
Half-life 1.3 hours
CAS number 16110-51-3 YesY
ATC code A07EB01 D11AH03 R01AC01 R03BC01 S01GX01
PubChem CID 2882
DrugBank DB01003
ChemSpider 2779 YesY
KEGG D07753 YesY
ChEBI CHEBI:59773 YesY
Chemical data
Formula C23H16O11 
Mol. mass 468.367 g/mol
 N (what is this?)  (verify)

Cromoglicic acid (INN) (also referred to as cromolyn (USAN), cromoglycate (former BAN), or cromoglicate) is traditionally described as a mast cell stabilizer, and is commonly marketed as the sodium salt sodium cromoglicate or cromolyn sodium. This drug prevents the release of inflammatory chemicals such as histamine from mast cells.

Because of their convenience (and perceived safety), leukotriene receptor antagonists have largely replaced it as the non-corticosteroid treatment of choice in the treatment of asthma. Cromoglicic acid requires administration four times daily, and does not provide additive benefit in combination with inhaled corticosteroids.[1]